{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:55:14Z","timestamp":1778266514908,"version":"3.51.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gaucher disease is a rare lysosomal storage disorder characterized by the accumulation of glucocerebroside lipids within multiple organs due to a deficiency of the lysosomal enzyme (acid \u03b2-glucosidase). It is an inherited autosomal recessive disease. The onset of symptoms can vary depending on disease type and severity, with milder forms presenting in adulthood. The main clinical manifestations include cytopenia, splenomegaly, hepatomegaly, and bone lesions. GD is characterized by several bone manifestations, such as osteopenia\/osteoporosis, focal lytic or sclerotic lesions, osteonecrosis acute or chronic bone pain, Erlenmeyer flask deformity, and subchondral joint collapse with secondary degenerative arthritis. In 70\u2013100% of patients affected by Gaucher disease type 1, clinical or radiographic evidence of bone disease occurs. Among bone complications, osteoporosis is very common, but its etiopathogenesis in GD is not completely clear. Results deriving from experimental studies support the hypothesis that there is an aberrant activity of both osteoclasts and osteoblasts due to several factors, resulting in impaired bone turnover. Bone complications represent the main cause of pain, disability, and reduced quality of life in these patients. Therefore, there is a need to enhance awareness among physicians on the skeletal manifestations throughout life of GD patients, in order to improve diagnosis and management of bone complications. In particular, this narrative review focuses on risk of bone fragility in GD, etiopathogenetic hypotheses, epidemiological data, diagnosis, monitoring, and treatment of osteoporosis in patients suffering from Gaucher disease, specifying the challenges not yet addressed.<\/jats:p>","DOI":"10.1007\/s00223-024-01340-y","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:48:20Z","timestamp":1737524900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Diagnosis and Therapy of Osteoporosis in Gaucher Disease"],"prefix":"10.1007","volume":"116","author":[{"given":"Gemma","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"4","key":"1340_CR1","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3111","volume":"12","author":"JN Stirnemann","year":"2010","unstructured":"Stirnemann JN, Belmatoug CV (2010) Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther 12(4):R156","journal-title":"Arthritis Res Ther"},{"key":"1340_CR2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, Deegan P (2019) Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res 34:996\u20131013","journal-title":"J Bone Miner Res"},{"key":"1340_CR3","unstructured":"Hughes DA, Pastores GM (2000) Gaucher Disease Jul 27 [updated 2023 Dec 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132024. PMID: 20301446"},{"issue":"15","key":"1340_CR4","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","volume":"19","author":"AM Vaccaro","year":"2010","unstructured":"Vaccaro AM, Motta M, Tatti M, Scarpa S, Masuelli L, Bhat M, Vanier MT, Tylki-Szymanska A, Salvioli R (2010) Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum Mol Genet 19(15):2987\u20132997","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1340_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hch036","volume":"97","author":"RH Lachmann","year":"2004","unstructured":"Lachmann RH, Grant IR, Halsall D, Cox TM (2004) Twin pairs showing discordance of phenotype in adult Gaucher\u2019s disease. QJM 97(4):199\u2013204","journal-title":"QJM"},{"key":"1340_CR6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","volume":"68","author":"M Biegstraaten","year":"2018","unstructured":"Biegstraaten M, Cox TM, Belmatoug N, Berger MG et al (2018) Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis 68:203\u2013208","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"1340_CR7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00223-014-9923-y","volume":"95","author":"G Marcucci","year":"2014","unstructured":"Marcucci G, Zimran A, Bembi B et al (2014) Gaucher disease and bone manifestations. Calcif Tissue Int 95(6):477\u2013494","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 1","key":"1340_CR8","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","volume":"75","author":"RJ Wenstrup","year":"2002","unstructured":"Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(Suppl 1):A2-12","journal-title":"Br J Radiol"},{"issue":"1","key":"1340_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcmd.2015.10.001","volume":"56","author":"P Giraldo","year":"2016","unstructured":"Giraldo P, P\u00e9rez-L\u00f3pez J, N\u00fa\u00f1ez R et al (2016) Patients with type 1 Gaucher disease in Spain: a cross-sectional evaluation of health status. Blood Cells Mol Dis 56(1):23\u201330","journal-title":"Blood Cells Mol Dis"},{"key":"1340_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann J, Vigan M, Hamroun D et al (2012) (2012) The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis 7:77","journal-title":"Orphanet J Rare Dis"},{"issue":"23\u201324","key":"1340_CR11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","volume":"160","author":"P Mikosch","year":"2010","unstructured":"Mikosch P, Hughes D (2010) An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 160(23\u201324):609\u2013624","journal-title":"Wien Med Wochenschr"},{"key":"1340_CR12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajmg.a.32253","volume":"149A","author":"MA Faden","year":"2009","unstructured":"Faden MA, Krakow D, Ezgu F, Rimoin DL, Lachman RS (2009) The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am J Med Gen A 149A:1334\u20131345","journal-title":"Am J Med Gen A"},{"issue":"15","key":"1340_CR13","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau PM, Rafei M, Boivin M-N, Sun Y, Grabowski GA, Galipeau J (2009) Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114(15):3181\u20133190","journal-title":"Blood"},{"issue":"10","key":"1340_CR14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","volume":"43","author":"RS Kamath","year":"2014","unstructured":"Kamath RS, Lukina E, Watman N et al (2014) Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol 43(10):1353\u20131360","journal-title":"Skeletal Radiol"},{"issue":"1","key":"1340_CR15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J et al (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90(1):52\u201360","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1340_CR16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bcmd.2009.04.003","volume":"43","author":"A Zimran","year":"2009","unstructured":"Zimran A, Morris E, Mengel E et al (2009) The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 43(3):264\u2013288","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"1340_CR17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Solano V, P\u00e9rez-Calvo J-I, Giralt M, Rubio-F\u00e9lix D, Spanish Group on Gaucher Disease (2005) Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 14(2):453\u2013462","journal-title":"Qual Life Res"},{"issue":"9","key":"1340_CR18","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2106\/00004623-198668090-00011","volume":"68","author":"RS Bell","year":"1986","unstructured":"Bell RS, Mankin HJ, Doppelt SH (1986) Osteomyelitis in Gaucher disease. J Bone Joint Surg Am 68(9):1380\u20131388","journal-title":"J Bone Joint Surg Am"},{"key":"1340_CR19","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s003300000446","volume":"10","author":"LW Poll","year":"2000","unstructured":"Poll LW, Koch JA, vom Dahl S, Loxtermann E, Sarbia M, Niederau C, Ha\u00a8ussinger D, Mo\u00a8dder U, (2000) Extraosseous manifestation of Gaucher\u2019s disease type I: MR and histological appearance. Eur Radiol 10:1660\u20131663","journal-title":"Eur Radiol"},{"issue":"1","key":"1340_CR20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","volume":"46","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T (2011) Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 46(1):66\u201372","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"1340_CR21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","volume":"11","author":"GM Pastores","year":"1996","unstructured":"Pastores GM, Wallenstein S, Desnick RJ, Luckey MM (1996) Bone density in type 1 Gaucher disease. J Bone Miner Res 11(11):1801\u20131807","journal-title":"J Bone Miner Res"},{"issue":"8","key":"1340_CR22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","volume":"27","author":"A Khan","year":"2012","unstructured":"Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK (2012) Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J Bone Miner Res 27(8):1839\u20131848","journal-title":"J Bone Miner Res"},{"issue":"18","key":"1340_CR23","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160(18):2835\u20132843","journal-title":"Arch Intern Med"},{"issue":"4","key":"1340_CR24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00198-010-1342-y","volume":"22","author":"R-M Javier","year":"2011","unstructured":"Javier R-M, Hachulla E, Rose C et al (2011) Vertebral fractures in Gaucher disease type I: data from the French \u201cObservatoire\u201d on Gaucher disease (FROG). Osteoporos Int 22(4):1255\u20131261","journal-title":"Osteoporos Int"},{"issue":"11","key":"1340_CR25","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","volume":"18","author":"KL Stone","year":"2003","unstructured":"Stone KL, Seeley DG, Lui L-Y et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18(11):1947\u20131954","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1340_CR26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.beem.2014.08.010","volume":"29","author":"LA Clarke","year":"2015","unstructured":"Clarke LA, Hollak CEM (2015) The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders. Best Pract Res Clin Endocrinol Metab 29(2):219\u2013235","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"1340_CR27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/imj.16503","volume":"54","author":"S Piran","year":"2024","unstructured":"Piran S et al (2024) The natural history of Gaucher disease type 1 in 31 patients over a median of 15 years: a retrospective study. Int Med J 54(10):1661\u20131668","journal-title":"Int Med J"},{"issue":"2","key":"1340_CR28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2020.07.011","volume":"132","author":"PA Rozenfeld","year":"2021","unstructured":"Rozenfeld PA, Crivaro AN, Ormazabal M, Mucci JM, Bondar C, Delpino MV (2021) Unraveling the mystery of Gaucher bone density pathophysiology. Mol Genet Metab 132(2):76\u201385","journal-title":"Mol Genet Metab"},{"issue":"45","key":"1340_CR29","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","volume":"107","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Liu J, Yang M et al (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA 107(45):19473\u201319478","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1340_CR30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2013.04.006","volume":"51","author":"M Reed","year":"2013","unstructured":"Reed M, Baker RJ, Mehta AB, Hughes DA (2013) Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease. Blood Cells Mol Dis 51(3):185\u2013194","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"1340_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069293","volume":"8","author":"S Lecourt","year":"2013","unstructured":"Lecourt S, Mouly E, Freida D et al (2013) A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients. PLoS ONE 8(7):e69293","journal-title":"PLoS ONE"},{"issue":"6","key":"1340_CR32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10545-012-9476-z","volume":"35","author":"G Ciana","year":"2012","unstructured":"Ciana G, Deroma L, Franzil AM, Dardis A, Bembi B (2012) Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients. J Inherit Metab Dis 35(6):1101\u20131106","journal-title":"J Inherit Metab Dis"},{"issue":"13","key":"1340_CR33","doi-asserted-by":"crossref","first-page":"1029130","DOI":"10.3389\/fendo.2022.1029130","volume":"24","author":"MM Ivanova","year":"2022","unstructured":"Ivanova MM, Dao J, Kasaci N, Friedman A, Noll L, Goker-Alpan O (2022) Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease. Front Endocrinol (Lausanne) 24(13):1029130","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1340_CR34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-024-03132-x","volume":"19","author":"CH Wang","year":"2024","unstructured":"Wang CH, Huang YN, Liao WL et al (2024) GBA1 as a risk gene for osteoporosis in the specific populations and its role in the development of Gaucher disease. Orphanet J Rare Dis 19(1):144","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1340_CR35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","volume":"28","author":"C Drugan","year":"2002","unstructured":"Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Craciun AM (2002) Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 28(1):13\u201320","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"1340_CR36","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V96.5.1969","volume":"96","author":"MT Moran","year":"2000","unstructured":"Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM (2000) Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96(5):1969\u20131978","journal-title":"Blood"},{"issue":"23","key":"1340_CR37","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","volume":"95","author":"P Saftig","year":"1998","unstructured":"Saftig P, Hunziker E, Wehmeyer O et al (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95(23):13453\u201313458","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1340_CR38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","volume":"96","author":"P Mikosch","year":"2009","unstructured":"Mikosch P, Reed M, Stettner H, Baker R, Mehta AB, Hughes DA (2009) Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. Mol Genet Metab 96(3):113\u2013120","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1340_CR39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-014-0280-4","volume":"47","author":"FM Ulivieri","year":"2014","unstructured":"Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JB, Caudarella R (2014) Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine 47(2):435\u2013448","journal-title":"Endocrine"},{"key":"1340_CR40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie D, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1340_CR41","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","volume":"34","author":"E Shevroja","year":"2023","unstructured":"Shevroja E et al (2023) Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int 34(9):1501\u20131529","journal-title":"Osteoporos Int"},{"key":"1340_CR42","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/jbmr.499","volume":"26","author":"D Hans","year":"2011","unstructured":"Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone micro-architecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26:2762\u20132769","journal-title":"J Bone Miner Res"},{"key":"1340_CR43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","volume":"78","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Gl\u00fcer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice: a consensus report of a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group. Bone 78:216\u2013224","journal-title":"Bone"},{"issue":"6","key":"1340_CR44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00223-019-00536-x","volume":"104","author":"B Oliveri","year":"2019","unstructured":"Oliveri B, Gonz\u00e1lez D, Quiroga F, Silva C, Rozenfeld P (2019) A comprehensive study of bone manifestations in adult Gaucher disease type 1 patients in Argentina. Calcif Tissue Int 104(6):650\u2013657","journal-title":"Calcif Tissue Int"},{"key":"1340_CR45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bcmd.2017.06.003","volume":"68","author":"M Baldini","year":"2018","unstructured":"Baldini M, Casirati G, Ulivieri FM, Cassinerio E, Chalouhi KK, Poggiali E et al (2018) Skeletal involvement in type 1 Gaucher disease: not just bone mineral density. Blood Cells Mol Dis 68:148\u2013152","journal-title":"Blood Cells Mol Dis"},{"issue":"2007","key":"1340_CR46","first-page":"S9","volume":"41","author":"SL Bonnick","year":"2007","unstructured":"Bonnick SL (2007) HSA: beyond BMD with DXA. Bone 41(2007):S9-12","journal-title":"Bone"},{"issue":"1","key":"1340_CR47","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.212779","volume":"307","author":"S D\u2019Amore","year":"2023","unstructured":"D\u2019Amore S et al (2023) Radiographic cortical thickness index predicts fragility fracture in Gaucher disease. Radiology 307(1):e212779","journal-title":"Radiology"},{"key":"1340_CR48","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/jbmr.3121","volume":"32","author":"S Herrera","year":"2017","unstructured":"Herrera S, Perez-Lopez J, Molto-Abad M, Guerri-Fernandez G, Cabezudo E, Novelli S et al (2017) Assessment of bone health in patients with type 1 Gaucher disease using impact microindentation. J Bone Miner Res 32:1575\u20131581","journal-title":"J Bone Miner Res"},{"issue":"24","key":"1340_CR49","first-page":"100606","volume":"30","author":"K Sidhu","year":"2020","unstructured":"Sidhu K, Boyd SK, Khan A (2020) Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat. Mol Genet Metab Rep 30(24):100606","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"1340_CR50","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","volume":"50","author":"CL Leibson","year":"2002","unstructured":"Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ (2002) Mortality, disability, and nursing home use for persons with and without hipfracture: a population-based study. J Am Geriatr Soc 50(10):1644\u20131650","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1340_CR51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-020-01656-6","volume":"16","author":"P Deegan","year":"2021","unstructured":"Deegan P, Khan A, Camelo JS Jr, Batista JL, Weinreb N (2021) The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients. Orphanet J Rare Dis 16(1):9","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1340_CR52","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385\u2013397","journal-title":"Osteoporos Int"},{"issue":"1","key":"1340_CR53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.GIM.0000105742.39917.EF","volume":"6","author":"X Li","year":"2004","unstructured":"Li X, Chen S, Kantorovich V, Cheng LS, Cohn DH, Rotter JI et al (2004) Genetic determinants of osteoporosis susceptibility in a female Ashkenazi Jewish population. Genet Med 6(1):33\u201337","journal-title":"Genet Med"},{"issue":"3","key":"1340_CR54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocd.2023.101369","volume":"26","author":"JA Shepherd","year":"2023","unstructured":"Shepherd JA (2023) Positions of the international society for clinical densitometry and their etiology: a scoping review. J Clin Densitom 26(3):101369","journal-title":"J Clin Densitom"},{"issue":"7","key":"1340_CR55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","volume":"90","author":"A Zimran","year":"2015","unstructured":"Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D (2015) Seven- year safety and efficacy with velaglucerase alfa for treatment- na\u00efve adult patients with type 1 Gaucher disease. Am J Hematol 90(7):577\u2013583","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"1340_CR56","first-page":"S19","volume":"90","author":"J Charrow","year":"2015","unstructured":"Charrow J, Scott CR (2015) Long-term treatment outcomes in Gaucher disease. Am J Hematol 90(Suppl 1):S19-24","journal-title":"Am J Hematol"},{"issue":"1","key":"1340_CR57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-3476(96)70203-2","volume":"129","author":"P Kaplan","year":"1996","unstructured":"Kaplan P, Mazur A, Manor O et al (1996) Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129(1):149\u2013153","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"1340_CR58","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1259\/bjr.75.suppl_1.750037","volume":"75","author":"B Bembi","year":"2002","unstructured":"Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ (2002) Bone complications in children with Gaucher disease. Br J Radiol 75(Suppl 1):A37-44","journal-title":"Br J Radiol"},{"issue":"3","key":"1340_CR59","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","volume":"108","author":"M De Fost","year":"2006","unstructured":"De Fost M, Hollak CEM, Groener JEM et al (2006) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108(3):830\u2013835","journal-title":"Blood"},{"issue":"5","key":"1340_CR60","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","volume":"104","author":"RJ Wenstrup","year":"2004","unstructured":"Wenstrup RJ, Bailey L, Grabowski GA et al (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104(5):1253\u20131257","journal-title":"Blood"},{"key":"1340_CR61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/8756-3282(94)90818-4","volume":"15","author":"S Adami","year":"1994","unstructured":"Adami S, Mian M, Gatti P et al (1994) Effects of two oral doses of alendronate in the treatment of Paget\u2019s disease of bone. Bone 15:415\u2013417","journal-title":"Bone"},{"key":"1340_CR62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9343(96)00227-6","volume":"101","author":"IR Reid","year":"1996","unstructured":"Reid IR, Nicholson GC, Weinstein RS et al (1996) Biochemical and radiologic improvement in Paget\u2019s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 101:341\u2013348","journal-title":"Am J Med"},{"key":"1340_CR63","first-page":"23","volume":"22","author":"A Khan","year":"2015","unstructured":"Khan A, Hanley DA, McNeil C, Boyd S (2015) Improvement in bone mineral density and architecture in a patient with Gaucher disease using teriparatide. JIMD Rep 22:23\u201328","journal-title":"JIMD Rep"},{"issue":"1","key":"1340_CR64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E et al (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14(1):59","journal-title":"Arch Osteoporos"},{"issue":"5","key":"1340_CR65","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/hmg\/ddx442","volume":"27","author":"LM Panicker","year":"2018","unstructured":"Panicker LM, Srikanth MP, Castro-Gomes T, Miller D, Andrews NW, Feldman RA (2018) Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition. Hum Mol Genet 27(5):811\u2013822","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1340_CR66","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymgme.2020.06.003","volume":"130","author":"A Crivaro","year":"2020","unstructured":"Crivaro A, Bondar C, Mucci JM, Ormazabal M, Feldman RA, Delpino MV, Rozenfeld PA (2020) Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis. Mol Genet Metab 130(4):274\u2013282","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1340_CR67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217780","volume":"14","author":"AN Crivaro","year":"2019","unstructured":"Crivaro AN, Mucci JM, Bondar CM, Ormazabal ME, Ceci R, Simonaro C, Rozenfeld PA (2019) Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease. PLoS ONE 14(5):e0217780","journal-title":"PLoS ONE"},{"issue":"8","key":"1340_CR68","doi-asserted-by":"crossref","first-page":"ziae071","DOI":"10.1093\/jbmrpl\/ziae071","volume":"8","author":"A Barbato","year":"2024","unstructured":"Barbato A et al (2024) Imiglucerase, cholecalciferol, and bone-diet in skeletal health management of type I Gaucher disease patients: a pilot study and systematic review. JBMR Plus 8(8):ziae071","journal-title":"JBMR Plus"},{"issue":"12","key":"1340_CR69","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s12325-014-0174-0","volume":"31","author":"G Giuffrida","year":"2014","unstructured":"Giuffrida G, Cappellini MD, Carubbi F, Di Rocco M, Iolascon G (2014) Management of bone disease in Gaucher disease type 1: clinical practice. Adv Ther 31(12):1197\u20131212","journal-title":"Adv Ther"},{"issue":"4","key":"1340_CR70","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ (2009) Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 147(4):561\u2013570","journal-title":"Br J Haematol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01340-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:20:32Z","timestamp":1766755232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01340-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01340-y","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GM: Support for attending meetings and\/or travel: Amgen; MLB: Honoraria: Amgen, Ascendis, Bruno, Farmaceutici, Calcilytix, Kyowa Kirin, UCB; Grants and\/or speaker, support for attending meetings and\/or travel: Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa Therapeutics, SPA, Takeda, Theramex, UCB; Consultant: Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, Smoke-Free World Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"31"}}